Publicacións (20) Publicacións de José Manuel Paz González

filter_list

2025

  1. Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study

    PLoS ONE, Vol. 20, Núm. 3 March

  2. Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson’s Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose

    Brain Sciences, Vol. 15, Núm. 7

  3. Impact of device-aided therapies on quality of life in patients with Parkinson’s disease. A comparative multicenter observational study

    Journal of Neural Transmission

  4. Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

    Movement Disorders Clinical Practice

2023

  1. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  2. Response to levodopa in Parkinson's disease over time. A 4-year follow-up study

    Parkinsonism and Related Disorders, Vol. 116

  3. Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints

    Journal of Clinical Neurology (Korea), Vol. 19, Núm. 4, pp. 344-357

  4. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

    Brain and Behavior, Vol. 13, Núm. 12

2022

  1. Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group

    Journal of Parkinson's Disease, Vol. 12, Núm. 1, pp. 315-331

  2. Isolated speech-induced lingual dystonia successfully treated with botulinum neurotoxin

    Neurologia

  3. Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study

    Neurological Sciences, Vol. 43, Núm. 4, pp. 2537-2544

  4. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

    Brain Sciences, Vol. 12, Núm. 11

2021

  1. Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

    Advances in Therapy, Vol. 38, Núm. 10, pp. 5398-5411

  2. Predictors of clinically significant quality of life impairment in Parkinson’s disease

    npj Parkinson's Disease, Vol. 7, Núm. 1

2020

  1. Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross-Sectional Survey of 568 Spanish Patients

    Movement Disorders, Vol. 35, Núm. 10, pp. 1712-1716

  2. Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

    Scientific Reports, Vol. 10, Núm. 1

  3. Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression

    Journal of the Neurological Sciences, Vol. 418

  4. The impact of freezing of gait on functional dependency in Parkinson’s disease with regard to motor phenotype

    Neurological Sciences, Vol. 41, Núm. 10, pp. 2883-2892

2019

  1. High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

    Journal of Neural Transmission, Vol. 126, Núm. 12, pp. 1599-1608

2008

  1. A retrospective study of the effectiveness of lamotrigine in monotherapy for the treatment of epileptic seizures. The ERELMO study

    Revista de Neurologia, Vol. 46, Núm. 4, pp. 197-202